[HTML][HTML] Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine

…, D Benkeser, HE Janes… - … England Journal of …, 2021 - Mass Medical Soc
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical …

D Follmann, HE Janes, OD Buhule, H Zhou… - Annals of internal …, 2022 - acpjournals.org
Background: Immunoassays for determining past SARS-CoV-2 infection have not been
systematically evaluated in vaccinated persons in comparison with unvaccinated persons. …

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

…, AB McDermott, Y Fong, HE Janes… - Science translational …, 2023 - science.org
The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials

DV Mehrotra, HE Janes, TR Fleming… - Annals of internal …, 2021 - acpjournals.org
Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will …

Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence

B Hanscom, HE Janes, PD Guarino… - JAIDS Journal of …, 2016 - journals.lww.com
The World Health Organization has issued an early release revision to its antiretroviral
guidelines in which PrEP (pre-exposure prophylaxis in the form of daily oral, fixed dose …

[HTML][HTML] Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

…, ME Sobieszczyk, L Corey, HE Janes… - The Journal of …, 2019 - Am Soc Clin Investig
HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant
adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered persons …

[HTML][HTML] Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

D Benkeser, Y Fong, HE Janes, EJ Kelly, I Hirsch… - npj Vaccines, 2023 - nature.com
In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …

Higher T-cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial

HE Janes, KW Cohen, N Frahm… - The Journal of …, 2017 - academic.oup.com
Background. It is important to identify vaccine-induced immune responses that predict the
preventative efficacy of a human immunodeficiency virus (HIV)–1 vaccine. We assessed T-cell …

A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial …

…, Y Fong, S Ferguson, HE Janes… - The Journal of …, 2018 - academic.oup.com
Background DSM265 is a selective inhibitor of Plasmodium dihydroorotate dehydrogenase
that fully protected against controlled human malarial infection (CHMI) by direct venous …

Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials

NS Hejazi, MJ van der Laan, HE Janes, PB Gilbert… - …, 2021 - academic.oup.com
The advent and subsequent widespread availability of preventive vaccines has altered the
course of public health over the past century. Despite this success, effective vaccines to …